VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE ...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...

VTX3232 is a CNS-penetrant, potent and selective inhibitor of the NLRP3 inflammasome. The single-center, open-label Phase 2a study evaluated a 40mg oral daily dose of VTX3232 in ten patients with ...

Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous system (CNS)-penetrant NLRP3 inhibitor, VTX3232, in individuals with ...

The results come from a phase 2a trial that evaluated a 40-mg oral daily dose of VTX3232 in 10 patients with early-stage, idiopathic Parkinson’s over a 28-day treatment period.

VTX3232 is geared toward neuroinflammatory and neurodegenerative conditions, including Parkinson’s disease, cardiometabolic disease, Alzheimer’s disease, and multiple sclerosis, among others.

SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...

VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE ...

VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE ...

VTX3232 is also being studied in a 12-week Phase 2 trial in participants with obesity and cardiometabolic risk factors; topline results expected in H2 2025 SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE ...